Skip to content
Clinical Trials – home
FinlandBack to Finland

Clinical trials in Jarvenpaa – page 30

403 clinical trials in Jarvenpaa, Finland. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Jarvenpaa at a glance
403
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

403 trials in Jarvenpaa

Open in trial search

Plasma cell myeloma

Not recruiting

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Study Comparing Asciminib with Other Drug Combinations for Adults with Newly Diagnosed Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Garetosmab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Pfizer Inc.
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Jarvenpaa

What the registry says about research in the country

01 Respiratory Virus Prevention

Innovative research focusing on respiratory syncytial virus (RSV) and influenza vaccines, evaluating new preventive approaches for both young and elderly populations.

  • RSV vaccine development for seniors
  • Influenza vaccine efficacy studies
  • Combined viral protection research

Multiple clinical trials are exploring breakthrough vaccine technologies, including mRNA platforms.

02 Meningococcal Disease Research

Comprehensive studies on meningococcal vaccines targeting multiple disease strains, with particular focus on protecting infants and young children.

  • Pentavalent vaccine development
  • Long-term immunity studies
  • Pediatric vaccination protocols

Research aims to enhance protection against various meningococcal serogroups through innovative conjugate vaccines.

03 Viral Disease Prevention

Advanced research into preventing cytomegalovirus and herpes zoster infections, utilizing cutting-edge vaccine technologies.

  • CMV prevention strategies
  • Herpes zoster vaccine efficacy
  • Pneumococcal protection studies

These trials focus on developing robust immune responses in specific target populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.